Document is current
Any future updates will be listed below
-
Authors
Munhall, Adam C. https://orcid.org/0000-0002-1960-5486
Eiwaz, Mahaba B.
Hebert, Jessica F.
Groat, Tahnee
Andeen, Nicole K.
Muruve, Daniel
Stewart, Ian J. https://orcid.org/0000-0001-6653-875X
Loss, Lindsay
Buzzard, Lydia
Liu, Moqing
Pierre, Lylord
Tinoco-Garcia, Louis
Durbin, Samantha
Beiling, Marissa
Minoza, Karen https://orcid.org/0009-0000-9521-8018
Garay, Joseph P. https://orcid.org/0000-0002-2287-3051
Schreiber, Martin A.
Hutchens, Michael P. https://orcid.org/0000-0001-8583-1812
- License Information
-
More Information
Article History
Received: 1 July 2025
Accepted: 20 January 2026
First Online: 12 March 2026
Competing interests
: Dr. Muruve is Co-founder and CSO of Arch Biopartners Inc, owner and licensee of the following patents on cilastatin for AKI. DPEP-1 binding compositions and methods of use. Robbins S, Senger D, Rahn J, Muruve DA, Lau A. US application 15/234,521 filed August 11, 2016, in reference to US provisional patent filed December 10, 2015. International application PCT/IB2016/001244 filed August 11, 2016. Use of cilastatin to reduce the nephrotoxicity of different compounds. Tejedor Jorge A, Lazaro Fernandez A, Camano Paez S, Torres Redondo AM, Lazaro Manero JA, Castilla Barba M, del Carmen De Lucas Collantes M. International application PCT/ES2008/070137 filed July 11, 2008. All other authors declare no competing interests.
